vebreltinib is an oral tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of non-small cell lung cancer (NSCLC) harboring specific gene mutations, such as MET exon14 skipping mutation or MET amplification. It inhibits the abnormally activated MET protein to block tumor growth signaling pathways and delay disease progression, with tumor shrinkage or stabilization observed in some patients.
Specific Mechanism of Action and Clinical Value
1. Indications
It is indicated for patients with advanced or metastatic non-small cell lung cancer, particularly those confirmed to have MET exon14 skipping mutation or MET amplification via genetic testing.
For patients with locally advanced NSCLC who have failed prior chemotherapy or immunotherapy, it may serve as a novel therapeutic option.
2. Mechanism of Action
Targeting the MET signaling pathway：Aberrant activation of the MET protein can promote cancer cell proliferation, invasion and metastasis. vebreltinib competitively binds to the ATP-binding site of the MET protein and inhibits its phosphorylation, thereby blocking the transduction of downstream pro-tumor signaling pathways (e.g., PI3K-AKT and RAS-MAPK pathways).
Anti-angiogenic effect: It indirectly inhibits vascular endothelial growth factor (VEGF)-related pathways, thus reducing tumor blood supply.
3. Clinical Efficacy
Clinical studies have shown that vebreltinib achieves an objective response rate (ORR) of 40%-50% in NSCLC patients with MET mutations, with a median progression-free survival (PFS) of approximately 10 months, which is significantly superior to conventional chemotherapy.
It may possess a certain capacity to cross the blood-brain barrier in patients with brain metastases, though this requires further clinical data to validate.
4. Common Adverse Reactions
Most adverse reactions are mild to moderate, including edema, nausea, fatigue, and anorexia.
Close vigilance is required for severe adverse reactions such as elevated liver enzymes and interstitial lung disease (ILD), and regular monitoring of liver function and pulmonary imaging is necessary.
Precautions for Use
Administration as directed by a physician
vebreltinib is a prescription-only medicine. Treatment regimens should be formulated based on genetic testing results, disease stage and individual patient conditions; the dosage should not be adjusted nor the medication discontinued without medical advice.
Contraindicated populations
It is contraindicated in patients with hypersensitivity to any component of the drug; use with caution in patients with severe hepatic and renal insufficiency. A comprehensive risk assessment is required for pregnant and lactating women before administration.
Drug-drug interactions
Concomitant use with potent CYP3A4 inhibitors or inducers may affect the plasma drug concentration of vebreltinib. Patients should inform their physicians of all other medications they are taking.
For patients who meet the indications, it is recommended to complete genetic testing and undergo treatment regimen evaluation at an oncology specialist department, and conduct regular follow-up to monitor treatment efficacy and safety during the medication period.
